Brought to you by 
Ascletis signs its first licensing deal, taking some rights to Alnylam's ALN-VSP
23 Jul 2019
Executive Summary
Alnylam Pharmaceuticals Inc. (RNAi therapies) has granted Ascletis Inc. (cancer and infectious disease treatments) exclusive rights to develop and sell in China (including Hong Kong, Macau, and Taiwan) its Phase II-ready liver cancer candidate ALN-VSP.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ascletis signs its first licensing deal, taking some rights to Alnylam's ALN-VSP
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice